Earnings call transcript: West Pharmaceutical Services Q4 2025 earnings beat expectations

robot
Abstract generation in progress

West Pharmaceutical Services (WST) reported strong Q4 2025 earnings, exceeding revenue and EPS expectations. The company posted an EPS of $2.04 against a forecast of $1.84, and revenue of $805 million compared to an anticipated $796.25 million, leading to a 4.07% rise in pre-market stock price. Key drivers include high-value product components, expansion in the GLP-1 market, and upgrades related to Annex 1 regulations.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)